← FDA ENFORCEMENT
D-0102-2024Class I

Pfizer Inc.

Recalling firm
Pfizer Inc.
Product type
Drug
Status
Terminated
Report date
2023-11-15
Distribution
Nationwide in the US and Puerto Rico. The products were not distributed to government accounts or foreign consignees.
Firm state
NY
Product quantity
3,200 vials
Initiated by
Voluntary: Firm initiated
SPEQ quality domain
Environmental Monitoring
Reason for recall

Presence of Particulate Matter: identified as glass.

Product description

2% Lidocaine HCl Injection, USP, 100mg/5mL(20mg/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector per carton, Rx only, Distributed by Hospira Inc., Lake Forest, IL 60045, NDC 0409-4903-11

Code / lot info

Lot#: GH6567, Exp. 7/1/2024

Other recalls SPEQ maps to Environmental Monitoring
2026-07-22Class IArgon Medical Devices, Inc2026-07-22Class IIOlympus Corporation of the Americas2026-07-22Class IIChiesi USA, Inc.2026-07-22Class IICareFusion 213, LLC
See all Environmental Monitoring recalls →

Data: U.S. FDA openFDA enforcement API. Recall details are as reported by the FDA. The quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification.